Chromosome 1p Loss and 1q Gain for Grading of Meningioma

作者：Alexander Landry, Justin Z. Wang, Vikas S. Patil, Jeff Liu, Chloe Gui, Yosef Ellenbogen, Andrew A. Ajisebutu, Leeor S. Yefet, Qingxia Wei, Olivia Singh, Julio Sosa, Sheila Mansouri, Aaron Cohen‐Gadol, Ghazaleh Tabatabai, Marcos Tatagiba, Felix Behling, Jill S. Barnholtz‐Sloan, Andrew Edward Sloan, Silky Chotai, Lola Blackwell Chambless, Alireza Mansouri, Serge Makarenko, Stephen S. F. Yip, Felix Ehret, David Capper, Derek S. Tsang, Jennifer A. Moliterno, Murat Günel, Pieter Wesseling, Felix Sahm, Kenneth Aldape, Andrew F. Gao, Gelareh Mohammed Zadeh, Farshad Nassiri · 发表于：JAMA Oncology · 年份：2025 · DOI：10.1001/jamaoncol.2025.0329 · 被引用次数：27 · 研究领域：Meningioma and schwannoma management、Glioma Diagnosis and Treatment、Brain Metastases and Treatment

Importance: The World Health Organization (WHO) classification of central nervous system tumors (CNS) grading for meningioma was updated in 2021 to include rare molecular features, namely homozygous deletions of CDKN2A or CDKN2B and TERT promotor alterations. Previous work, including the cIMPACT-NOW statement, has discussed the potential value of including chromosomal copy number alterations to help refine the current grading system. Objective: To identify chromosomal copy number alterations that could be used to improve the current CNS WHO grading of meningioma. Design, Setting, and Participants: In this cohort study, patients with surgically treated meningioma were followed-up until recurrence or progression of disease or death. Chromosomal copy number alterations were then correlated with progression-free survival (PFS) to identify new outcome biomarkers. This study included patients with a histopathological diagnosis of meningioma from multiple institutions in Canada, the US, and Germany, with molecular data collection starting in 2016. Data were analyzed from January to September 2024. Exposures: All patients underwent surgery for meningioma and a subset underwent radiation therapy. Main Outcomes and Measures: The main outcome was PFS. Cox regression analysis was used to identify copy number alterations associated with outcomes in the context of WHO grading. Results: Among 1964 patients with meningioma (1256 female; median [IQR] age, 58 [48-69] years) assessed, loss of c...